Futura Medical (FUM.L) Stock Analysis & Winston Score
Futura Medical is a small UK-based biotechnology company focused on developing medicines that are applied directly to the skin, known as transdermal drug delivery. Its main product is Eroxon, a gel treatment for erectile dysfunction that works quickly and is available without a prescription. The company sells to consumer healthcare markets, primarily targeting adults who want an over-the-counter alternative to prescription pills. Futura makes money by licensing its products and technology to larger pharmaceutical and consumer health companies, who then handle manufacturing and distribution. Eroxon has received regulatory approval in the US, UK, and parts of Europe, giving Futura a foothold in a large global market. However, the company is still in an early commercial stage, spends far more than it earns, and depends heavily on its partners successfully marketing Eroxon at scale — meaning slow consumer adoption or weak partner execution remains the central risk to its future growth.
Winston Score: 41/100 — Average
Mixed quality — meaningful strengths and weaknesses.
- Quality: Exceptional (30/30)
- Growth: Weak (1/20)
- Cash Flow: Weak (0/10)
- Stability: Data not available (0/10)
- Valuation: Data not available (0/10)
- Ownership: Good (8/15)
Key Facts
Price: 0.36 GBp
Market Cap: 1M GBp
Sector: Healthcare
Industry: Biotechnology
Exchange: London Stock Exchange


